Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Sölétormos G, et al. Among authors: tholander b. Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586. Int J Gynecol Cancer. 2016. PMID: 26588231 Free PMC article.
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.
Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM. Sölétormos G, et al. Among authors: tholander b. Clin Chem. 2013 Jan;59(1):52-9. doi: 10.1373/clinchem.2011.180778. Epub 2012 Oct 3. Clin Chem. 2013. PMID: 23034139
Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome.
von Heideman A, Tholander B, Grundmark B, Cajander S, Gerdin E, Holm L, Axelsson A, Rosenberg P, Mahteme H, Daniel E, Larsson R, Nygren P. von Heideman A, et al. Among authors: tholander b. Acta Oncol. 2014 Feb;53(2):242-50. doi: 10.3109/0284186X.2013.794956. Epub 2013 May 29. Acta Oncol. 2014. PMID: 23713890
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
Dahm-Kähler P, Holmberg E, Holtenman M, Rådestad AF, Borgfeldt C, Hjerpe E, Marcickiewicz J, Bjurberg M, Tholander B, Hellman K, Kjølhede P, Högberg T, Rosenberg P, Åvall-Lundqvist E, Stålberg K. Dahm-Kähler P, et al. Among authors: tholander b. Gynecol Oncol. 2021 Apr;161(1):244-250. doi: 10.1016/j.ygyno.2021.01.012. Epub 2021 Feb 10. Gynecol Oncol. 2021. PMID: 33581846
Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
Tholander B, Taube A, Lindgren A, Sjöberg O, Stendahl U, Kiviranta A, Hallman K, Holm L, Weiner E, Tamsen L. Tholander B, et al. Gynecol Oncol. 1990 Oct;39(1):16-25. doi: 10.1016/0090-8258(90)90393-y. Gynecol Oncol. 1990. PMID: 2227569
50 results